Bird Rock Bio Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Bird Rock Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011838
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bird Rock Bio Inc (Bird Rock Bio), formerly RuiYi Inc is a clinical stage biopharmaceutical company that develops immuno-inflammatory regulators. The company’s products under development include RYI-018 is a peripheral antagonist antibody to cannabinoid receptor 1 intended for the treatment of nonalcoholic steatohepatitis, fibrotic and metabolic diseases. Its Gerilimzumab, an anti IL-6 antibody indicated for moderate to severe rheumatoid arthritis, inflammatory and autoimmune diseases. Bird Rock Bio provides therapeutic antibodies, with clinical and commercial differentiation, against biologic targets. The company operates through research institutes and universities for its activities. Bird Rock Bio is headquartered in La Jolla, California, the US.

Bird Rock Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bird Rock Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
RuiYi Raises US$15 Million In Series B Financing 10
Anaphore Secures US$0.15 Million In Venture Financing 12
Partnerships 13
Bird Rock Bio Enters into agreement with GE Healthcare 13
Janssen Pharma Enters into Partnership with Bird Rock Bio 14
RuiYi Enters into Agreement with iHuman Institute to Develop Novel Antibodies 15
CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 16
Licensing Agreements 17
Bird Rock Bio Enters into Licensing Agreement with arGEN-X for ARGX-109 17
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 19
Bird Rock Bio Inc – Key Competitors 20
Bird Rock Bio Inc – Key Employees 21
Bird Rock Bio Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Clinical Trials 23
Jan 11, 2017: Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab 23
Jan 03, 2017: Bird Rock Bio Receives Approval from ANVISA and CONEP to Initiate the First Phase 2 Study in Brazil of Gerilimzumab for Rheumatoid Arthritis 24
Oct 27, 2016: Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab 25
Mar 15, 2016: argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody Against IL-6 to Treat Rheumatoid Arthritis 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bird Rock Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bird Rock Bio Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
RuiYi Raises US$15 Million In Series B Financing 10
Anaphore Secures US$0.15 Million In Venture Financing 12
Bird Rock Bio Enters into agreement with GE Healthcare 13
Janssen Pharma Enters into Partnership with Bird Rock Bio 14
RuiYi Enters into Agreement with iHuman Institute to Develop Novel Antibodies 15
CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 16
Bird Rock Bio Enters into Licensing Agreement with arGEN-X for ARGX-109 17
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 19
Bird Rock Bio Inc, Key Competitors 20
Bird Rock Bio Inc, Key Employees 21

★海外企業調査レポート[Bird Rock Bio Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Acuity Brands, Inc.:戦略・SWOT・企業財務分析
    Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Albany Molecular Research, Inc. (AMRI):企業の財務及び戦略的SWOT分析
    Albany Molecular Research, Inc. (AMRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Connected Solutions Group Pty Ltd. (CSV):企業の財務及び戦略的SWOT分析
    Summary Connected Solutions Group Pty Ltd. (CSG) is a technical service provider that offers print and communication solutions. The company provides enterprise solutions, business solutions, finance solutions, printers, photocopies, among others. CSG’s print services include colour printers, colour …
  • Compucom Software Limited (COMPUSOFT):企業概要、財務及び戦略的SWOT分析
    Summary Compucom Software Limited (CSL) is a software and education company. The company provides enterprise application development, IT infrastructure solutions, mobile solutions and products. It offers product such as internet or IVR based customer assistance reporting and expediting and interacti …
  • Aderans Co., Ltd.:企業概要・SWOT・財務分析
    Summary Canadean's "Aderans Co., Ltd. : Consumer Packaged Goods - Company Profile, SWOT and Financial Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business descri …
  • KaloBios Pharmaceuticals, Inc. (KBIO):企業の財務及び戦略的SWOT分析
    Summary KaloBios Pharmaceuticals, Inc. (KaloBios) is a biopharmaceutical company that offers therapies. The company develops monoclonal antibodies for the treatment of severe respiratory diseases and cancer. Its products include KB001-A, KB003, and KB004. KaloBios’s KB001-A, is used to treat pseudom …
  • BioPhausia AB(製薬・医療分野):企業M&A動向
    Summary BioPhausia AB (BioPhausia) is a pharmaceutical company. The company develops and sells prescription medicines. Its products include citodon, digoxin biophausia, egazil, laxabon, mollipect, morfin special, nitroglycerin biophausia, paraflex, probecid, solvezink, suscard, teovent, lithionit an …
  • ECA S.A.:企業の戦略・SWOT・財務分析
    SummaryECA S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - Det …
  • Maxis Communications Berhad:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Maxis Communications Berhad Mer …
  • TopiVert Ltd-製薬・医療分野:企業M&A・提携分析
    Summary TopiVert Ltd (TopiVert) is a drug development company that offers disease control solutions in inflammatory diseases of the gastrointestinal tract and the eye. The company develops and offers narrow spectrum kinase inhibitors (NSKI) for the treatment of chronic inflammatory diseases of gastr …
  • Medicyte GmbH:(医療機器分野)企業M&A及び提携動向
    Summary MediCyte GmbH (MediCyte) is a life science company. The company carries out controlled, scalable propagation and standardization of human primary cell products. It provides solutions in the areas of research, industrial and therapeutic applications. MediCyte’s products include upcyte, vericy …
  • Papa Bello Enterprises, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Papa Bello Enterprises, Inc. Me …
  • Flint Hills Resources, LP:企業の戦略的SWOT分析
    Flint Hills Resources, LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • NedSense enterprises N.V. (NEDSE):企業の財務及び戦略的SWOT分析
    Summary Nedsense Enterprises N.V. (NedSense) is an information technology company that develops, manufactures and supplies software solutions. The company’s solutions include design and creation, coloring, virtual sampling, presentation and cataloguing, and printing and workflow. NedSense’s solution …
  • Vanoil Energy Ltd. (VEL)(石油・ガス分野):企業M&A動向
    Summary Vanoil Energy Ltd. (Vanoil Energy) is an oil and gas company. The company explores and produces crude oil and natural gas properties. Its Kenya exploration property has processed over 1,500 line kilometers in the delineation of multiple structural leads in Blocks 3A and 3B. Vanoil Energy’s K …
  • Merus Labs International, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Merus Labs International, Inc. …
  • Hongkong and Shanghai Banking Corporation Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Hongkong and Shanghai Banking C …
  • Quality & Reliability S.A. (QUAL):企業財務及び戦略的SWOT分析
    Summary Quality & Reliability S.A. (Q & R) is a technology company that develops and provides software integration services. The company’s activities include development of integrated information systems, e-business solutions and document management systems, and implementation of enterprise resource …
  • NuStar Energy L.P.:企業の戦略・SWOT・財務分析
    SummaryNuStar Energy L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Find …
  • PanaHome Corporation (1924):企業概要、財務及び戦略的SWOT分析
    Summary PanaHome Corporation (PanaHome) is a construction service provider. The company provides housing, asset management and home remodeling services. Its services include custom built detached housing, detached house development, condominium development, home remodeling, construction of external …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆